Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

OBJECTIVE: To investigate the long-term safety and efficacy of empagliflozin, a sodium glucose cotransporter 2 inhibitor; sitagliptin; and metformin in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this randomized, open-label, 78-week extension study of two 12-week, blinded, dose-fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrannini, Ele, Berk, Andreas, Hantel, Stefan, Pinnetti, Sabine, Hach, Thomas, Woerle, Hans J., Broedl, Uli C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836134/
https://www.ncbi.nlm.nih.gov/pubmed/24186878
http://dx.doi.org/10.2337/dc13-0663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836134/
https://www.ncbi.nlm.nih.gov/pubmed/24186878
http://dx.doi.org/10.2337/dc13-0663

Ejemplares similares